This article reveals the need for study of the market of drugs used in hepatosis, it is rather difficult to substantiate and systematize the treatment of fatty hepatosis with such a variety of causes that cause it. therapy should be aimed at eliminating the causes, at stopping the syndromes of impaired digestion and absorption, at restoring the function of the liver and biliary system. this excludes the intake of certain drugs and alcohol abuse.
Babak O. Ya. Chronic hepatitis. - K .: Blitz-Print, 1999
Golubchikov M.V. Statistical insight into the ailments of the population of Ukraine on the ailments of the liver and the youngsters // Modern gastroenterology and hepatology. - 2000.
Grigor'eva G.S., Kirichok L.M., Konakhovich N.F. ta in. //. Complex solution as a way of increasing a certain amount of microelements // Sovr. probl. toxicology. - 1998.
Vovk A.D., Tatyanka N.V., Lyashok. OV, Slobodyanik M. Ya. Therapeutic efficacy of Antral in viral hepatitis B // Prospects for the creation of synthetic gspatoprotectors in Ukraine: Abstracts. report republ. scientific. -practice. conf. - Kharkov, 1993
Krasnyuk EP, Pustylnik ED The effectiveness of the new hepatoprotector Antral in the treatment of patients with chronic toxic liver damage // Medical. a business. - 1994.
Petrunya A.M. Introduced to Antral on immune status and microcirculation in patients with chronic viral hepatitis // Infectious diseases. - Vip. IV. - Lviv: Esculap, 1996
Rachkauskas GS Clinical and immunological parameters in the treatment of patients with chronic alcoholism with liver pathology by Antral // Ecology of the industrial region of Donbas: Materials of IV sciences. -practice. conf. - Kiev; Luhansk, 1994.